Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Wilson it's easy to miss these things as our company has so many diverse products. Transplant diagnostics seems to be an emerging growth area so hopefully we can become a key player in this area.
Dohhh Tks balance didn't even see that.
They are broadening their products in transplant diagnostics. Here is one the past rns regarding this.
https://www.investegate.co.uk/novacyt-s-a-/rns/novacyt-launches-two-new-molecular-diagnostic-kits/201812210700032048L/
Kaeren; Haha, Mixing caps & l/c. I had the very same thought, but you beat me to it! LOL. Pesky work got in the way.
Be VeRy iNtErEsTiNg To SeE lAtE tRaDeS tOdAy , ExPeCt A lOt oF bUy's. K
Bkv. Kit
A4uk where dyou get that from please.
this is all very encouraging. i'd imagine they had a big list of things they wanted to develop and bring to market but were limited by funding. next few months could be very interesting to see how they build their pipeline
Allah4uk; That is good news that they are diversifying into other areas, more strings to the bow etc.
And...thank you for spacing your post out, all those capitals close together previously were making my old eyes go skatty.
ONE OF THE UPCOMING PRODUCTS IS A TEST FOR TRANSPLANTS.
TRANSPLANTS = VALUABLE NICHE MARKET = HIGH MARGINS
https://www.youtube.com/watch?v=amjoVe7ihck&feature=youtu.be - video of recent presentation.
48:45
M&A strategy - "We are clear what we need to do.
We are looking to add revenues and to add to profitability of the group.
By doing this we will 'offset' or 'hedge' the risk associated with the loss of C-19 revenues at some point in the future."
(at last, the CEO talking about the number 1 subject that dissuades new investors from investing).
"I would hasten to add that we do not see that happening near term and believe, unfortunately, that Covid-19 testing will be here for some time to come."
So the company has got themselves as close as possible to PHE and those persons uniquely qualified to state the future needs of the health service in terms of testing and test capabilities.
They are meeting these needs by developing products (e.g. Winterplex) that the govnt. say they want at break neck speed.
(If the British Govnt's testing requirements are being met by NCYT's new products, - I don't see how other govnts requirements would differ materially).
The company are also working with Astra and GSK at Cambridge.
If there is a better placed Biotech to understand the needs of testers and testing, I'd like to hear from them.
So when Graham states they are 'hedging' against losing income from C-19 revenues "at some point in the future"
and that "we do not see that (loss of C-19 revenues) happening near term", for me that is unequivocal.
There are 2 maybe more products in the pipeline, so lets hope they launch soon.
No worries B2HS2L, easily done with the amount of posts on this bb. The more it is repeated the better in my view. Here's the link, again, in case anyone missed it.
https://www.sharebuyers.co.uk/shares/should-i-buy-novacyt-shares-now-5-reasons-why/
Plus the 6th reason: We have no debt - this is no mentioned, it was all cleared in the first few months of the year.
Plenty of upside to come - hugely undervalued still. IMO
GLA, DYOR, £1bn, SP £15 minimum
Apologies Hillseeker, repeated your link, my bad.
From a Maddog8 post, Tuesday 20:58 -
5 reasons why there is plenty more upside due
https://www.sharebuyers.co.uk/shares/should-i-buy-novacyt-shares-now-5-reasons-why/
- 6 good reasons why you haven't.
One initial thought that many people new to this share may be thinking is, have I missed the boat? The share has already risen more than 40 fold, there cannot be any more upside - surely?
Well that's what I thought when I only dipped in with a small investment at 169, only to watch it rapidly move to £5 and then retrace. That was a whole world ago in the early days and it has steadily built a much more sound position, and as posters below are saying, since then the company has been transformed. We now have a new floor or foundation on which to build and the sky appears to be th limit. But don't take our word for it.
The attached Share Buyers article from 29th September (it has been posted before, but easily missed with recent amount of traffic) gives 5 good reasons to invest in Novacyt right now:
https://www.sharebuyers.co.uk/shares/should-i-buy-novacyt-shares-now-5-reasons-why/
A 6th reason is we have no debt - this is no mentioned, it was all cleared in the first few months of the year.
Plenty of upside to come - hugely undervalued still. IMO
GLA, DYOR, £1bn, SP £15 minimum